A Diagnostics & Imaging Week
Zoll Medical (Chelmsford, Massachusetts) and Masimo (Irvine, California) reported a multi-year technology agreement to integrate Masimo's Rainbow SET technology into Zoll E Series defibrillators.
The agreement allows Zoll to manufacture these defibrillators with this technology, which non-invasively and continuously measures carbon monoxide (SpCO) and methemoglobin (SpMet) levels in the blood.
"Masimo Rainbow SET Pulse CO-Oximetry non-invasively delivers the advanced clinical intelligence that today's EMS and fire professionals need to accurately diagnose and treat victims of carbon monoxide poisoning," said Zoll Chairman/CEO Richard Packer. "This agreement will allow us to add this important parameter in the future to help rescuers advance their lifesaving efforts."
Carbon monoxide (CO) is a dangerous silent killer that is often very difficult to diagnose. If left untreated, it can have significant morbidity and mortality consequences.
Masimo Rainbow SET has the potential to help clinicians improve patient outcomes through more rapid diagnosis of potentially life-threatening conditions – including carbon monoxide poisoning and methemoglobinemia – allowing them to make better and earlier treatment decisions.
In other agreements/contracts news:
• Ensemble Discovery (Cambridge, Massachusetts) said that it has extended its collaboration with Roche (Basel, Switzerland) to apply its diagnostic technology to personalized cancer therapy. The collaboration will deploy Ensemble's assays, which are based upon DNA-Programmed Chemistry, in human clinical studies to analyze combinations of Epidermal Growth Factor Receptors (EGFR) present in cancer tissues.
This family of receptors is one of the most actively targeted in modern oncology therapy. The goal of the project is to develop product prototypes that detect EGFR receptor dimers (protein complexes made up of two identical molecules) in human cancer tissue samples and ultimately to use those products to improve the management of cancer patients and their therapy.
• SciQuest (Cary, North Carolina) has formed a strategic alliance with Qiagen (Venlo, the Netherlands) to help Qiagen's customers realize the efficiencies of procurement automation through faster, easier access to crucial diagnostics and research supplies.
"We were one of the first suppliers to join the SciQuest Supplier Network in 2000. We decided to do so because we knew that procurement automation can offer a win-win situation: customers realize the efficiencies they seek and Qiagen can efficiently compete for greater market share," said Matthias Raquet, senior director, global service solutions at Qiagen. "Our commitment to enhance our ecommerce presence, of which this alliance is a part, stems from our continual commitment to make working with Qiagen as easy and effective as possible."
As part of the alliance, Qiagen will work closely with customers to explore ways they can take advantage of ecommerce capabilities to generate costs savings and process efficiencies. Through SciQuest's eprocurement solution suite, customers can realize the benefits of procurement automation to easily access and order Qiagen consumables, instruments and services online.
• Dilon Technologies (Newport News, Virginia) has formed an alliance with Terason Ultrasound (Burlington, Massachusetts) to offer an expanded imaging capability when molecular breast imaging and ultrasound may be required.
Breast-specific gamma imaging (BSGI) is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers, particularly for women with high risk factors or that present with questionable mammograms. With BSGI, metabolic activity is assessed and cancerous cells generally display as "hot spots."
The Terason t3000 ultrasound system offers premium imaging performance with the portability and functionality of a laptop. When used as a complement to the Dilon 6800 Gamma Camera, physicians are able to move from BSGI to ultrasound without leaving the exam room.